Liver Diseases Therapeutics Market 2015 - 2020

Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Hepatitis is the largest segment among these diseases, of which hepatitis C is the biggest and fastest growing segment. The liver diseases caused by viral infections, alcoholism, obesity, diabetes, among many other reasons. Some of the diseases are not curable such as liver cirrhosis or non-alcoholic fatty liver disease, and are usually not diagnosed early. This leads to the substantial damage of the liver, which proves to be life-threatening. Some types of hepatitis are preventable or treatable by using vaccines and indicated drugs.

Technavio's analysts forecast the global liver diseases therapeutics market to grow at a CAGR of 15.61% over the period 2014-2019.

Browse Detail Report With TOC @ http://www.hexareports.com/report/global-liver-diseases-therapeutics-market/details

Covered in this report

This report covers the present scenario and the growth prospects of the global liver diseases therapeutics market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of liver diseases.

Based on disease indication, the market is segmented as follows:

Non-alcoholic fatty liver disease (includes non-alcoholic steatohepatitis)

Liver cirrhosis

Liver cancer

Hepatitis (Hepatitis A, B, and C)

This report includes a discussion of the market in the following three regions:

Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil

EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE

APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and...